Walleye Capital LLC Acquires New Holdings in Maze Therapeutics, Inc. $MAZE

Walleye Capital LLC acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 27,945 shares of the company’s stock, valued at approximately $834,000.

A number of other hedge funds also recently bought and sold shares of MAZE. Royal Bank of Canada boosted its position in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics in the 4th quarter worth $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the 4th quarter worth $43,000. California State Teachers Retirement System boosted its position in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $27.68 on Friday. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The firm has a market cap of $1.53 billion, a PE ratio of -10.94 and a beta of 2.14. Maze Therapeutics, Inc. has a 12 month low of $12.81 and a 12 month high of $53.65. The stock has a fifty day moving average price of $27.10 and a 200-day moving average price of $34.46.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Equities research analysts predict that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $28.02, for a total value of $210,150.00. Following the completion of the sale, the insider owned 26,250 shares of the company’s stock, valued at approximately $735,525. This trade represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 14,609 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total value of $436,809.10. Following the sale, the chief marketing officer owned 14,609 shares in the company, valued at $436,809.10. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 141,470 shares of company stock worth $3,887,939. 5.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Truist Financial reduced their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. JPMorgan Chase & Co. raised their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.